Analysis of Risk Factors of Coagulation Dysfunction and Hemorrhage in Newly Diagnosed Hyperleukocytic Acute Myeloma Leukemia

Table 5

Logistics analysis of influencing factors for abnormal coagulation function (≥1 abnormal among 5 data items) in patients with HAML.

	Wald	Exp (B)	S.E.	95% CI	value
FLT3-ITD	4.305	1.875	0.280	0.084–0.232	0.230
NPM1	0.967	0.619	0.829	0.619–5.516	0.631
CEBPA	6.069	1.833	0.733	0.323–10.407	0.089
PLT	0.155	1.014	0.035	0.947–1.086	0.693
Hb	0.220	0.995	0.011	0.975–1.016	0.501
Neutrophils	3.028	1.100	0.055	0.988–1.224	0.296
RBC	1.091	0.742	0.285	0.424–1.299	0.596
Sex	0.282	0.733	0.584	0.233–2.305	0.112
Age	2.530	1.026	0.016	0.994–1.020	0.752
HLA-DR+	0.625	2.412	1.113	2.471–21.378	0.722
CD13+	10.793	0.200	0.490	0.579–22.794	0.712
CD38+	4.236	5.136	0.795	0.22–4.931	0.117
CD33+	0.256	0.714	0.665	0.194–2.628	0.613
WBC >200 × 10^9//L	0.057	1.158	0.613	0.348–3.847	0.811
Abnormal liver function	0.051	1.143	0.594	0.295–3.288	0.135
Abnormal renal function	0.010	0.984	0.615	0.991–1.001	0.831
FAB type	7.735	0.145	1.282	0.012–1.791	0.102
Infection	9.927	1.143	0.688	0.032–0.471	0.007
Tumor burden	0.049	1.003	0.015	0.974–1.033	0.825
Respiratory failure	9.650	1.667	0.614	0.015–0.498	0.008

.